RxDoctor Payments Data

Fatima Khan, MD

Internal Medicine · Pearland, TXNPI 1629280441

Payments from drug & device makers

$2,574in general payments, 2019–2025

Across 35 payments — averaging $73.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Abiomed$125
  • Amgen$99
  • Lexicon Pharmaceuticals, Inc.$95
  • Exact Sciences$64
  • Pfizer$63
  • plus $130 from 4 others

What the payments were for

  • Food & beverage$2,574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott19$1,998
Abiomed1$125
Amgen1$99
Lexicon Pharmaceuticals, Inc.1$95
Exact Sciences4$64
Pfizer2$63
Novo Nordisk2$41
GSK2$40
Merck2$37
Bolder Surgical, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,574 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$42,525
Medicare patients
176
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$67,628
EliquisApixaban14$21,874
MounjaroTirzepatide18$15,419
TrulicityDulaglutide12$15,014
Tresiba Flextouch U-200Insulin Degludec15$14,548
JanuviaSitagliptin Phosphate13$13,985
GemtesaVibegron13$6,394
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,822
Gabapentin93$2,012
Bupropion XlBupropion Hcl67$1,891
Duloxetine Hcl46$1,707
Atorvastatin Calcium158$1,679
Losartan Potassium142$1,577
Levothyroxine Sodium107$1,179
Rosuvastatin Calcium102$1,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$67,62849 claims
PfizerEliquis$63$21,87414 claims
MerckJanuvia$37$13,98513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →